文献速递银屑病与炎症性皮肤病

司库奇尤单抗在中重度银屑病患者中治疗5年显示出高持续疗效和良好安全性(SCULPTURE扩展研究)

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-03-22

SCULPTURE扩展研究评估司库奇尤单抗治疗中重度银屑病5年的疗效与安全性。第1年168例进入扩展期,第5年末126例完成300mg每4周治疗。PASI 75/90/100应答从第1年(88.9%、68.5%、43.8%)持续至第5年(88.5%、66.4%、41%),DLQI 0/1应答从72.7%维持至65.5%,安全性与前2/3期项目一致,无累积或非预期安全问题。

要点

  • 司库奇尤单抗300mg每4周治疗5年,PASI 75应答率第1年88.9%、第5年88.5%。
  • PASI 90和PASI 100应答第1年分别为68.5%和43.8%,第5年分别为66.4%和41%。
  • DLQI 0/1应答第1年72.7%、第5年65.5%,安全性良好无累积或非预期问题。

核心结论

  • 司库奇尤单抗300mg治疗在中重度银屑病患者中5年内提供高且持续的皮损清除和生命质量改善。
  • 司库奇尤单抗2/3期项目中确立的良好安全性维持至5年。

研究设计与样本

  • SCULPTURE核心研究中第12周PASI 75应答者继续接受皮下司库奇尤单抗至第1年,之后进入扩展期按核心试验方案继续治疗。
  • 治疗双盲至第3年末,第4年起开放标签;本文聚焦300mg固定间隔(每4周)治疗,即标签推荐剂量。
  • 第1年168例进入扩展研究,第5年末126例完成300mg每4周治疗。
  • 疗效数据主要按观察病例报告,另以多重插补(MI)和末次观测结转(LOCF)作为支持性分析。

主要发现

  • 第1年PASI 75、90、100应答率分别为88.9%、68.5%、43.8%,第5年分别为88.5%、66.4%、41%。
  • PASI应答在观察病例、MI或LOCF分析下均一致。
  • 与核心研究基线相比,5年间平均PASI平均改善约90%。
  • DLQI 0/1应答持续至5年:第1年72.7%,第5年65.5%。
  • 司库奇尤单抗安全性保持良好,未发现累积或非预期安全问题。

关键数值与推荐

  • 第12周PASI 75应答者继续接受皮下司库奇尤单抗至第1年,此后进入扩展期按核心试验方案继续治疗。
  • 本文聚焦300mg固定间隔(每4周)治疗,即标签推荐剂量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy and a favourable safety profile in the treatment of moderate-to-severe psoriasis and psoriatic arthritis. OBJECTIVE: To assess the efficacy and safety of secukinumab through 5 years of treatment in moderate-to-severe psoriasis. METHODS: In the core SCULPTURE study, Psoriasis Area and Severity Index (PASI) 75 responders at Week 12 continued receiving subcutaneous secukinumab until Year 1. Thereafter, patients entered the extension phase and continued treatment as per the core trial. Treatment was double-blinded until the end of Year 3 and open-label from Year 4. Here, we focus on the 300 mg fixed-interval (every 4 weeks) treatment, the recommended per label dose. Efficacy data are primarily reported as observed, but multiple imputation (MI) and last observation carried forward (LOCF) techniques were also undertaken as supportive analyses. RESULTS: At Year 1, 168 patients entered the extension study and at the end of Year 5, 126 patients completed 300 mg (every 4 weeks) treatment. PASI 75/90/100 responses at Year 1 (88.9%, 68.5% and 43.8%, respectively) were sustained to Year 5 (88.5%, 66.4% and 41%). PASI responses were consistent regardless of the analysis undertaken (as observed, MI, or LOCF). The average improvement in mean PASI was approximately 90% through 5 years compared with core study baseline. DLQI (dermatology life quality index) 0/1 response also sustained through 5 years (72.7% at Year 1 and 65.5% at Year 5). The safety profile of secukinumab remained favourable, with no cumulative or unexpected safety concerns identified. CONCLUSION: Secukinumab 300 mg treatment delivered high and sustained levels of skin clearance and improved quality of life through 5 years in patients with moderate-to-severe psoriasis. Favourable safety established in the secukinumab phase 2/3 programme was maintained through 5 years.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018. PMID: 29444376. doi:10.1111/jdv.14878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。